Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

1.63
-0.0500-2.98%
Post-market: 1.59-0.0400-2.45%19:44 EDT
Volume:3.67M
Turnover:5.98M
Market Cap:690.60M
PE:-11.76
High:1.70
Open:1.66
Low:1.58
Close:1.68
52wk High:1.83
52wk Low:0.3200
Shares:423.68M
Float Shares:418.00M
Volume Ratio:1.19
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1387
EPS(LYR):-0.1387
ROE:-39.72%
ROA:-12.65%
PB:6.42
PE(LYR):-11.76

Loading ...

Stock Track | Lexicon Pharmaceuticals Surges 5.28% on Upcoming Jefferies Conference Participation

Stock Track
·
Nov 12, 2025

Stock Track | Lexicon Pharmaceuticals Soars 5.28% on Upcoming Jefferies Conference Participation

Stock Track
·
Nov 12, 2025

Lexicon Pharmaceuticals to Join Jefferies London Healthcare Conference

Reuters
·
Nov 11, 2025

Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes

Reuters
·
Nov 10, 2025

Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025

TIPRANKS
·
Nov 10, 2025

Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Pre-Market on $75 Million Stock Offering News

Stock Track
·
Nov 07, 2025

Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Following $75 Million Stock Offering Announcement

Stock Track
·
Nov 07, 2025

Stock Track | Lexicon Pharmaceuticals Plunges 7.69% on $75 Million Stock Offering Announcement

Stock Track
·
Nov 07, 2025

BRIEF-Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing

Reuters
·
Nov 07, 2025

Lexicon Pharmaceuticals Files Prospectus for Stock Sale

TIPRANKS
·
Nov 07, 2025

Lexicon Pharmaceuticals Inc Files for Offering of up to $75 Mln of Common Stock - SEC Filing

THOMSON REUTERS
·
Nov 07, 2025

Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM)

TIPRANKS
·
Nov 07, 2025

Stock Track | Lexicon Pharmaceuticals Soars 5.05% on Better-Than-Expected Q3 Results and Revenue Surge

Stock Track
·
Nov 07, 2025

Lexicon Pharma Q3 net loss narrows as R&D costs drops

Reuters
·
Nov 06, 2025

Lexicon Pharmaceuticals Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $14.182M Beat $4.649M Estimate

Benzinga
·
Nov 06, 2025

BRIEF-Lexicon Pharmaceuticals Q3 EPS USD -0.04

Reuters
·
Nov 06, 2025

Lexicon Pharmaceuticals Inc - FDA End-of-Phase 2 Meeting for Pilavapadin in Dpnp by Year-End

THOMSON REUTERS
·
Nov 06, 2025

Lexicon Pharmaceuticals Q3 Product Revenue USD 1.008 Million

THOMSON REUTERS
·
Nov 06, 2025

Lexicon Pharmaceuticals Inc - Co Has $145 Mln in Cash and Investments as of Sept 30

THOMSON REUTERS
·
Nov 06, 2025

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

THOMSON REUTERS
·
Nov 06, 2025